

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

PRECLINICAL RESULTS OF KRAS G12C INHIBITOR IN COMBINATION WITH SHP2 INHIBITOR WILL BE PRESENTED AT THE ESMO ASIA CONGRESS 2022

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medical Oncology ASIA (ESMO ASIA) Congress from December 2, 2022 to December 4, 2022.

The results of preclinical study showed that JAB-21822 in combination with JAB-3312 could synergistically inhibit tumor growth in multiple KRAS G12C inhibitor-resistant models, suggesting that the combination of JAB-21822 and JAB-3312 may overcome adaptive resistance to KRAS G12C inhibitor in cancer patients. Jacobio is currently conducting a clinical trial of JAB-21822 in combination with JAB-3312 (ClinicalTrials.gov Identifier: NCT05288205).

About the Abstract:

Track	Developmental therapeutics
Title	Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
Format	Poster presentation
Abstract Number	30P
Time	December 3, 2022

Please visit the official website of ESMO ASIA for more information: <https://www.esmo.org/meeting-calendar/esmo-asia-congress-2022>

About JAB-21822

JAB-21822 is an oral, small molecule KRAS G12C inhibitor independently developed by the Company. The Company has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients harbouring KRAS G12C mutation with advanced solid tumors, including pivotal clinical trial to treat non-small cell lung cancer in China; monotherapy for STK11 co-mutated non-small cell lung cancer in the front-line setting; combination therapy with SHP2 inhibitor JAB-3312, anti-PD-1 monoclonal antibody and cetuximab.

About JAB-3312

JAB-3312 is a high-selective SHP2 allosteric inhibitor. Jacobio is currently conducting clinical trials of JAB-3312 in China and the United States, and JAB-3312 has been granted orphan drug designation for esophageal cancer (including esophageal squamous cell carcinoma) by the U.S. Food and Drug Administration (FDA). Jacobio has signed a global, strategic collaboration agreement to develop and commercialise SHP2 inhibitors with AbbVie on June 1, 2020.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, KRAS G12C Inhibitor JAB-21822 and SHP2 inhibitor JAB-3312 and combination therapies of JAB-21822 and JAB-3312 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board of Directors
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, December 2, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Daqing CAI and Dr. Ge WU as independent non-executive Directors.